Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|22|2|237-263

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.22, Iss.2, 2014-12, pp. : 237-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging

By  

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 6, 2010-06 ,pp. : 527-539

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitors: novel anticancer agents

By Mani S.   Wang C.   Wu K.   Francis R.   Pestell R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1849-1870

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics

By  

Current Medicinal Chemistry, Vol. 7, Iss. 12, 2000-12 ,pp. : 1213-1245

Bentham Science Publishers

Access to resources Recommend Favorite

The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs

By  

Current Cancer Drug Targets, Vol. 12, Iss. 2, 2012-02 ,pp. : 85-96

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Cyclin-Dependent Kinase Inhibition. Purine-Based Derivatives as Anti-Cancer Agents. Roles and Perspectives for the Future

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 9, 2002-09 ,pp. : 1037-1050

Bentham Science Publishers

Access to resources Recommend Favorite